NSP 306
Latest Information Update: 06 Nov 1997
Price :
$50 *
At a glance
- Originator Nippon Soda
- Class Antithrombotics; Small molecules
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 06 Nov 1997 No-Development-Reported for Thrombosis in Japan (Unknown route)
- 31 Mar 1995 New profile
- 31 Mar 1995 Preclinical development for Thrombosis in Japan (Unknown route)